EUCTR2012-003101-10-FR进行中（未招募）1 期
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following criteria:
- •1) Between the ages of = 6 months and < 18 years of age
- •2) Written informed consent and written informed assent (if applicable)
- •3) Must have histologically proven B-cell ALL or B-cell lymphoblastic lymphoma
- •4) Measurable or evaluable disease
- •5) Disease status:
- •Subjects must have relapsed or refractory disease and received at least 1 standard chemotherapy and either 1 salvage regimen or allogeneic HSCT.
- •In event of relapse after prior allogeneic HSCT, subjects must be at least 3 months post-transplant, have no evidence of active graft-vs-host disease, and been off immunosuppression for at least 4 weeks
- •Must have resolution of the acute toxic effects to = Grade 2 from prior chemotherapy before entry, in the opinion of the investigator
- •6) For non-leukemic subjects, an absolute neutrophil count (ANC) > 1000/µL, and platelet count > 50,000/mm2 are required, unless cytopenias are judged by the investigator to be due to underlying disease (ie, potentially reversible with anti-neoplastic therapy).
- •7) Adequate Performance status.
- •8) Subjects with central nervous system (CNS) status 1 or 2 are eligible only in the absence of neurologic symptoms, such as cranial nerve palsy, suggestive of CNS leukemia.
- •9) Sexually active subjects must agree to use an approved method of contraception or abstinence to meet eligibility criteria.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 76
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any of the following would exclude the subject from participation in the study:
- •1) Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
- •2) Concurrent enrollment in another clinical study, unless it is a non-interventional, observational study or the subject is in the follow-up period from a previous study, or prior sponsor approval is obtained
- •3) Employees of the study site directly involved with the study at the site of enrollment, or immediate family members of such individuals
- •4) Isolated testicular or CNS ALL
- •5) Inadequate hepatic function
- •6) Inadequate renal function
- •7) Radiologically-detected CNS lymphoma
- •8) Laboratory findings consistent with Grade = 3 disseminated intravascular coagulation (DIC) or any Grade 2 DIC that does not correct
- •9) Hyperleukocytosis (WBC = 50,000/µL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
- •10) Pregnant or breast-feeding females
- •11) Prior treatment with CAT-3888 (BL22), moxetumomab pasudotox, or any pseudomonas-exotoxin-containing compound
- •12) Prior treatment with any anticancer biologic therapy within 2 weeks prior to enrollment, including but not limited to therapeutic monoclonal antibodies or antibody-drug conjugates
- •13) Systemic chemotherapy = 2 weeks (6 weeks for nitrosoureas) and radiation therapy = 3 weeks prior to starting study drug with exceptions per protocol
- •14) Other investigational antineoplastic agents within 30 days prior to Cycle 1, Dose of study treatment
- •15) Human immunodeficiency virus (HIV) positive serology
- •16) Seropositivity for hepatitis B (HBsAg) or hepatitis C (HCV antibody)
- •17) Clinically significant ophthalmologic findings during the screening
- •18) Uncontrolled, symptomatic, intercurrent illness that would limit study compliance
- •19) Presence of a second invasive malignancy
- •20) Any physical, social, or psychiatric condition, or any other condition which in the opinion of the investigator would prevent effective study cooperation or participation
- •21) Uncontrolled pulmonary infection, presence of pulmonary edema
- •22) Inadequate oxygen saturation
- •23) Serum albumin < 2 g/dL
- •24) Radioimmunotherapy within 2 years prior to study enrollment
- •25) Subject with prior history of thrombotic microangiopathy or HUS.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2, Multicenter Study in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic LymphomaPediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell OriginMedDRA version: 18.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10003939Term: B-lymphoblastic lymphoma (Kiel Classification)System Organ Class: 100000004864EUCTR2012-003101-10-NLMedImmune, LLC76
进行中（未招募）
不适用
A Phase 2, Multicenter Study in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic LymphomaRelapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell OriginMedDRA version: 16.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 16.0Level: LLTClassification code 10003939Term: B-lymphoblastic lymphoma (Kiel Classification)System Organ Class: 100000004864EUCTR2012-003101-10-ESMedImmune, LLC76
进行中（未招募）
不适用
A Phase 2, Multicenter Study in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic LymphomaEUCTR2012-003101-10-DEMedImmune, LLC76
尚未招募
2 期
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell OrigiPediatric Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma10024324NL-OMON41557MedImmune, LLC4
进行中（未招募）
不适用
A Phase 2, Multicenter Study in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic LymphomaRelapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell OriginMedDRA version: 14.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10003939Term: B-lymphoblastic lymphoma (Kiel Classification)System Organ Class: 100000004864EUCTR2012-003101-10-ITMedImmune, LLC76